Abstract

Tumor-associated macrophages (TAMs) of the immune microenvironment play an important role in the Diffuse Large B-cell Lymphoma (DLBCL) pathogenesis. This research aimed to characterize the expression of macrophage colony-stimulating factor 1 receptor (CSF1R) at the gene and protein level in correlation with survival. First, the immunohistochemical expression of CSF1R was analyzed in a series of 198 cases from Tokai University Hospital and two patterns of histological expression were found, a TAMs, and a diffuse B-lymphocytes pattern. The clinicopathological correlations showed that the CSF1R + TAMs pattern associated with a poor progression-free survival of the patients, disease progression, higher MYC proto-oncogene expression, lower MDM2 expression, BCL2 translocation, and a MYD88 L265P mutation. Conversely, a diffuse CSF1R + B-cells pattern was associated with a favorable progression-free survival. Second, the histological expression of CSF1R was also correlated with 10 CSF1R-related markers including CSF1, STAT3, NFKB1, Ki67, MYC, PD-L1, TNFAIP8, IKAROS, CD163, and CD68. CSF1R moderately correlated with STAT3, TNFAIP8, CD68, and CD163 in the cases with the CSF1R + TAMs pattern. In addition, machine learning modeling predicted the CSF1R immunohistochemical expression with high accuracy using regression, generalized linear, an artificial intelligence neural network (multilayer perceptron), and support vector machine (SVM) analyses. Finally, a multilayer perceptron analysis predicted the genes associated with the CSF1R gene expression using the GEO GSE10846 DLBCL series of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), with correlation to the whole set of 20,683 genes as well as with an immuno-oncology cancer panel of 1790 genes. In addition, CSF1R positively correlated with SIRPA and inversely with CD47. In conclusion, the CSF1R histological pattern correlated with the progression-free survival of the patients of the Tokai series, and predictive analytics is a feasible strategy in DLBCL.

Highlights

  • Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent histological subtypes of non-Hodgkin lymphoma (NHL) in the Western countries, representing approximately 25% of the cases

  • The staining for colony-stimulating factor 1 receptor (CSF1R) was performed in 10 reactive tonsils using an autostainer and, under the microscope, the slides showed that the CSF1R-positive cells had a morphology macrophage

  • In this research about DLBCL, we have found that the immunohistochemical expression of CSF1R was variable

Read more

Summary

Introduction

Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent histological subtypes of non-Hodgkin lymphoma (NHL) in the Western countries, representing approximately 25% of the cases. DLBCL not-otherwise specified (NOS) is characterized for being a heterogeneous disease because of the morphological characteristics, the biological background, and the genetic alterations [1]. Organization (WHO) [2], DLBCL has some separate diagnostic categories including the. T-cell/histiocyte rich large B-cell lymphoma, the primary DLBCL of the mediastinum, and the intravascular lymphoma, etc. DLBCL can be cured in around 50% of the cases with current therapy, mainly based on the R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The International Prognostic Index (IPI) and its derivatives are the main tools being used to stratify the prognosis of the patients with DLBCL. The IPI includes the following variables: age, serum lactate dehydrogenase, Eastern Cooperative Oncology

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call